August 2026 Research Update

This month added reassurance that IL-6 blocking medicines are commonly linked with improvement for idiopathic multicentric Castleman disease (iMCD) in real-world care, but it also highlighted that some people need other options. A small Canadian cohort reported that most iMCD patients treated with siltuximab or tocilizumab had at least a partial response, across several iMCD subtypes. A separate single-patient, lab-based analysis suggested sirolimus (an mTOR inhibitor) may reduce multiple immune signals in someone whose iMCD did not respond to tocilizumab, but this needs confirmation in larger studies. [1] [2]

In the Canadian cohort of 23 biopsy-confirmed Castleman disease patients, 15 had multicentric disease and were further classified as iMCD-TAFRO, iMCD-IPL, or iMCD-NOS. Among those treated with siltuximab or tocilizumab, the study reported at least partial responses in all iMCD-TAFRO and iMCD-IPL cases and in most iMCD-NOS cases. This supports the idea that IL-6 targeted treatment can be helpful for many people with iMCD, even though the data were retrospective and from a single center. [1]

For iMCD that does not respond to IL-6 blockade, a translational report followed one person receiving sirolimus and measured many blood proteins over 16 weeks. Several immune mediators decreased steadily through week 12, and the analysis also reported suppression of multiple immune activation pathways (including interferon and TNF-related signaling) through weeks 12 to 16. Because this was one patient and focused on lab signals rather than comparing many patients, it mainly serves as an early signal about possible biology to test in future controlled studies. [2]

For patients and caregivers, these studies mostly add context rather than changing anything immediately. The real-world cohort strengthens the picture that siltuximab and tocilizumab are often linked with improvement in iMCD, while also showing that the path to diagnosis and treatment can differ by subtype. The sirolimus report is early research from a single person, so it cannot tell how often it works, but it helps clarify that treatment may affect more than just IL-6-related inflammation in some cases. [1] [2]

This month connected Castleman disease to broader body effects in two complementary ways: what happens in organs like the kidneys, and what signals are active inside lymph nodes. A kidney-focused cohort found that a specific small-vessel injury pattern in the kidneys was often linked to iMCD and could improve when the underlying condition was addressed. Separately, proteomics of lymph node tissue reported that different Castleman subtypes had different molecular patterns, including immune signals and scarring-related pathways, which helps explain why subtypes can look and behave differently. [3] [4]

In a single-center cohort of 32 people with biopsy-proven glomerular microangiopathy (a small-blood-vessel injury in the kidney), iMCD was one of the most common underlying conditions reported. Everyone had protein in the urine, and acute kidney injury was also frequent; many patients had remission of urine protein and improved kidney function after the underlying cause was treated. The study also described that kidney biopsy patterns differed by cause, which matters because it suggests that similar kidney test results can come from different mechanisms. [3]

A separate tissue study mapped proteins inside lymph nodes from different Castleman subtypes and reported that iMCD could be distinguished from unicentric Castleman disease by systemic complement activation signals. It also reported that iMCD-TAFRO showed higher levels of proteins linked to blood vessel growth, interferon signaling, and fibrosis, and that these signals appeared in different areas of the lymph node. This is laboratory research, so it does not predict an individual patient's course, but it helps clarify what biological pathways may be driving subtype differences. [4]

For patients, these studies mainly help explain why Castleman disease can affect more than lymph nodes. The kidney cohort suggests that when kidney problems are part of the illness, improvement in urine protein and kidney function was often seen after the underlying disease was treated, although the exact treatments varied and were not tested head-to-head. The lymph node proteomics work is earlier-stage research, but it supports the idea that Castleman subtypes may involve different immune and scarring pathways, which could matter later for developing more targeted tests or treatments. [3] [4]

This month reinforced that diagnosing Castleman disease can be difficult for practical reasons: some biopsy methods may not capture enough tissue, and some other conditions can closely resemble Castleman disease. Several case-based reports described how larger tissue samples (for example, excisional biopsy or newer bronchoscopy tools) helped reach a clear diagnosis when initial sampling was unclear. Alongside this, an international protocol described progress toward a patient-reported symptom scale for iMCD, aiming to measure symptom burden in a consistent way across studies. [5] [6] [7] [8]

A case report described a person whose abdominal lymph node enlargement looked like Castleman disease but was ultimately diagnosed as familial Mediterranean fever, underscoring that look-alike conditions exist. Another report of iMCD-NOS described a diagnostic delay and highlighted that excisional lymph node biopsy helped establish the diagnosis after earlier workup. Together, these reports emphasize that the same outward picture (enlarged nodes and inflammation) can come from different causes, and that the diagnostic path can affect how quickly the right label is reached. [5] [7]

In a case series of three women with unicentric Castleman disease presenting as a single chest mass, standard needle sampling during bronchoscopy (EBUS-TBNA) was nondiagnostic in all cases. When clinicians used EBUS-guided intranodal forceps or cryobiopsy, they obtained enough preserved tissue structure to make the diagnosis, and two people who had surgery reported symptom resolution. This adds a practical message: for some hard-to-reach nodes, the type of biopsy can determine whether a diagnosis is possible. [6]

Other single-patient reports added examples of how Castleman disease can show up in unusual places and how confirmation can change the plan. One report described unicentric Castleman disease in the submandibular gland region that was treated with complete surgical excision and had disease-free follow-up for more than 3 years. Another described a person with Castleman disease who developed a kidney mass that looked like cancer on imaging but was shown on biopsy to be extramedullary hematopoiesis (blood-forming tissue outside the bone marrow), leading to observation rather than surgery. [9] [10]

Two additional case reports highlighted diagnostic complexity in specific settings, but details were limited in one. A report in a person living with HIV described HHV-8-associated multicentric Castleman disease and noted that HHV-8 staining on lymph node tissue supported the diagnosis, with rituximab plus ongoing antiretroviral therapy followed by resolution of pleural effusions and remission at 12 months. Another case described mesenteric hyaline vascular Castleman disease presenting with acute intestinal obstruction, but the available summary did not provide outcome details. [11] [12]

Finally, an international protocol reported ongoing development of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale, a questionnaire meant to capture iMCD symptoms directly from patients. Stage 3 data collection was completed with 51 participants and follow-up work is ongoing to estimate what amount of change is meaningful. This does not change care now, but it supports more consistent tracking of symptoms in future research and may help patients' experiences be measured more clearly in studies. [8]

For patients and caregivers, these studies mainly clarify why diagnosis can take time and why second steps in testing sometimes happen. Case-based evidence cannot predict what will happen for most people, but it shows that Castleman disease can be mimicked by other illnesses and that small or limited biopsies may miss the needed tissue structure. The symptom scale work is early and does not guide decisions yet, but it may matter later by allowing research studies to describe symptom changes in a clearer, more comparable way. [5] [6] [8]